Our exhibitors

CIRTA Biomed logo

Biomed Ltd | Stand 6

Biomed is one of the few pharmaceutical companies that continue to manufacture in New Zealand and employ kiwis.

We continue to operate a fully fledged injection production plant. The company offers a comprehensive range of products such as IV fluids, PCA's, epidurals, intrathecal bags and syringes.

Our CAPS department compounds a full range of TPN customized for the local market.

CIRTA Obex Insides logo

Insides Company & Obex Medical | Stand 4

The Insides Company is the leading provider of therapeutic chyme reinfusion solutions for intestinal failure.

Obex is an industry leader in advancing clinical education, and has a high level of clinical and technical expertise with a strong focus on meeting the changing needs of healthcare in Australasia. Obex’s purpose is to meet the needs of healthcare professionals with the supply of minimally invasive consumable and implantable devices which will enable the delivery of the best diagnosis and therapy to ensure best outcomes for patients.

CIRTA Janssen logo

Janssen | Table top 3

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

CIRTA Nestle logo

Nestlé Health Science | Table top 1

Nestlé Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. We aim to pioneer the development and application of evolving science to create a new role for nutrition in disease prevention and management for consumers, patients, healthcare professionals and our partners in healthcare.

CIRTA Nutricia logo

Nutricia Ltd | Table top 2

Since 1896, Nutricia has pioneered nutritional solutions that help people live longer, more joyful and healthier lives. Building on more than a century of research and innovation, Nutricia has harnessed the power of life-changing and life-saving nutrition to create a leading specialized nutrition portfolio that can change a health trajectory for life. With its nutritional solutions, Nutricia supports healthy growth and development during the first 1000 days and helps to address some of the world’s biggest health challenges; pre-term birth, faltering growth, food allergy, rare metabolic diseases, age-related conditions and chronic disease, such as frailty, cancer, stroke and early Alzheimer’s disease.

CIRTA NZMS logo updated

New Zealand Medical & Scientific | Stand 5

New Zealand Medical & Scientific, founded in 1982, provides the very best in clinical, diagnostic and consumer healthcare technology nationwide. The committed and friendly team are devoted to providing expert advice and unparalleled support for you and your patients.

Medicina – ENFit Enteral Feeding Systems and Gastroenterology devices to improve patient safety and care.
Bio- CER -HaemoCer Plus – a fast, effective and safe haemostatic powder.
SERB - Collatamp, a surgeon’s choice. The gentamycin impregnated collagen dressing proven to reduce SSI.

CIRTA Vectiv Bio logo

VectivBio | Virtual exhibitor

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global Phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).